features: Immuno-Oncology

First-line therapy in urothelial carcinoma: KEYNOTE-361 & DANUBE

Read More

Urothelial carcinoma updates presented at ESMO 2020: JAVELIN Bladder 100

Read More

The Lung Cancer Sessions

A three-part session with experts Solange Peters, Martin Reck, and Sanjay Popat, who discuss the latest updates in lung cancer…

Read More

ONS EONS Congress Round Table

Read More

Sig3 mutation and immune score determine responses to combination PARP and PD-1 inhibition in ovarian cancer

Immune checkpoint inhibitors have shown promising therapeutic outcomes in many types of cancer, but ovarian cancer has been an exception….

Read More

Use of pembrolizumab in patients with PS2 NSCLC

Clinical trials assessing the efficacy of pembrolizumab have previously enrolled patients with performance status (PS) 0–1. However, almost a fifth…

Read More

CAR T-cell therapy guided by scorpion toxin for glioblastoma

The first chimeric antigen receptor T-cell (CAR T-cell) therapy using chlorotoxin (CLTX), a toxin found in the venom of scorpions,…

Read More

FDA accepts subcutaneous combination of pertuzumab and trastuzumab for HER2+ breast cancer

Breast cancer is the most common type of malignancy in women.1 Human epidermal growth factor receptor 2 (HER2) positive breast…

Read More

Killer T-cell discovery at Cardiff

Cellular therapies are an exciting area in cancer research and clinical trials. The most widely known, CAR T-cell therapy, has…

Read More

FDA Approves Bevacizumab Biosimilar

Bevacizumab-bvzr (Zirabev; Pfizer), a biosimilar to bevacizumab (Avastin; Genentech) has been given the go-ahead by the FDA for five indications….

Read More
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals